Ascendis Pharma A (ASND) Operating Expenses (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Operating Expenses data on file, last reported at -$239.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 10.88% year-over-year to -$239.2 million; the trailing twelve-month figure through Mar 2026 stood at -$357.2 million (down 52.53% YoY), and the FY2025 full-year result was -$110.6 million, down 252.28% from the prior year.
• Operating Expenses declined to -$239.2 million in Q1 2026, from -$110.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $203.2 million in Q2 2025 to a low of -$239.2 million in Q1 2026.
• A 5-year average of $18.3 million and a median of $28.6 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 548.61% in 2023 and plunged 256.82% in 2025, its largest moves.
• Tracing ASND's Operating Expenses over 5 years: stood at -$97.4 million in 2022, then surged by 37.74% to -$60.6 million in 2023, then surged by 48.9% to -$31.0 million in 2024, then sank by 256.82% to -$110.6 million in 2025, then sank by 116.27% to -$239.2 million in 2026.
• Business Quant data shows ASND's Operating Expenses at -$239.2 million in Q1 2026, -$110.6 million in Q4 2025, and -$210.8 million in Q3 2025.